Back to Atlas
BSemi-durableStandard research/education caution
CMP-0662
Research chemical/reference listing
Palopegteriparatide
General biohacking / research
Bioactive effect candidate for Atlas review
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Bioactive compound
- Primary mechanism
- Mechanism requires verification
- Primary market use
- General biohacking / research
Pharmacology
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~1–7 days (half-life-extended peptide class estimate)
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Palopegteriparatide (Transcon PTH) is a prodrug of parathyroid hormone PTH 1-34, which can maintain normal and stable calcium concentrations without the need for calcium and active vitamin D replacement. Palopegteriparatide can be used in research on hypoparathyroidism.